Mylan NV (NASDAQ:MYL) Director Buys $353,600.00 in Stock

Mylan NV (NASDAQ:MYL) Director Melina E. Higgins acquired 20,000 shares of the business’s stock in a transaction on Thursday, August 15th. The shares were purchased at an average price of $17.68 per share, with a total value of $353,600.00. Following the completion of the purchase, the director now owns 33,120 shares in the company, valued at approximately $585,561.60. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Shares of Mylan stock traded up $0.66 on Monday, hitting $19.19. 5,649,536 shares of the company were exchanged, compared to its average volume of 6,969,182. The stock has a market capitalization of $9.08 billion, a price-to-earnings ratio of 4.19, a price-to-earnings-growth ratio of 0.83 and a beta of 1.77. The company has a 50-day moving average price of $19.09 and a 200 day moving average price of $23.55. Mylan NV has a 1-year low of $16.63 and a 1-year high of $39.59. The company has a quick ratio of 0.77, a current ratio of 1.37 and a debt-to-equity ratio of 1.15.

Mylan (NASDAQ:MYL) last issued its earnings results on Monday, July 29th. The company reported $1.03 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.95 by $0.08. The business had revenue of $2.85 billion for the quarter, compared to analysts’ expectations of $2.82 billion. Mylan had a return on equity of 18.93% and a net margin of 0.30%. The business’s revenue for the quarter was up 1.5% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.07 EPS. Research analysts forecast that Mylan NV will post 4.3 EPS for the current year.

Several institutional investors have recently modified their holdings of the company. Vicus Capital boosted its holdings in shares of Mylan by 5.3% during the 1st quarter. Vicus Capital now owns 7,874 shares of the company’s stock worth $223,000 after purchasing an additional 396 shares during the last quarter. Global Retirement Partners LLC lifted its holdings in Mylan by 107.1% in the first quarter. Global Retirement Partners LLC now owns 967 shares of the company’s stock valued at $27,000 after acquiring an additional 500 shares during the last quarter. Securian Asset Management Inc lifted its holdings in Mylan by 1.0% in the first quarter. Securian Asset Management Inc now owns 52,672 shares of the company’s stock valued at $1,493,000 after acquiring an additional 529 shares during the last quarter. Piedmont Investment Advisors Inc. lifted its holdings in Mylan by 8.7% in the first quarter. Piedmont Investment Advisors Inc. now owns 8,335 shares of the company’s stock valued at $236,000 after acquiring an additional 670 shares during the last quarter. Finally, Eaton Vance Management lifted its holdings in Mylan by 7.1% in the second quarter. Eaton Vance Management now owns 10,164 shares of the company’s stock valued at $194,000 after acquiring an additional 677 shares during the last quarter. Institutional investors and hedge funds own 83.27% of the company’s stock.

Several research firms have commented on MYL. BidaskClub upgraded Mylan from a “sell” rating to a “hold” rating in a research note on Thursday, June 20th. BMO Capital Markets set a $36.00 price objective on Mylan and gave the stock a “buy” rating in a research note on Wednesday, May 8th. Credit Suisse Group reiterated a “buy” rating and set a $34.50 price objective on shares of Mylan in a research note on Wednesday, July 31st. Wells Fargo & Co lowered Mylan from an “outperform” rating to a “market perform” rating and cut their price objective for the stock from $33.00 to $22.00 in a research note on Tuesday, May 7th. Finally, Cantor Fitzgerald cut their price objective on Mylan from $31.00 to $18.00 and set a “neutral” rating for the company in a research note on Wednesday, June 12th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and fourteen have issued a buy rating to the company’s stock. Mylan presently has a consensus rating of “Buy” and an average price target of $30.43.

Mylan Company Profile

Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter (OTC) pharmaceutical products in North America, Europe, and internationally. It offers active pharmaceutical ingredients and finished dosage forms; and antiretroviral medicines to treat HIV/AIDS.

See Also: How to find the components of the quick ratio

Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.